FDA Clearance Tracker · P980016-S555
EVERA MRI XT DR/VR SURESCAN,EVERA MRI S DR/VR SURESCAN ICDS AND PROGRAMMER SOFTWARE
Last checked: Nov 20, 2026Latest source record: Apr 28, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Apr 28, 2016
Approved
Time to decision
198 days
Received Oct 13, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P980016-S555
- Device name
- EVERA MRI XT DR/VR SURESCAN,EVERA MRI S DR/VR SURESCAN ICDS AND PROGRAMMER SOFTWARE
- Applicant location
- Mounds View, MN
- Received
- Oct 13, 2015
- Decided
- Apr 28, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P980016
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the expansion of MRI conditional labeling for the Advisa and Evera SureScan Systems to 3T MRI.
Source documents
Other decisions for Medtronic Cardiac Rhythm Disease Management
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.